Radnor, PA – November 25, 2024 – Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that a new version of its GlobalSubmit regulatory submissions software…
The article “Recent Applications of Pharmacometrics and Systems Pharmacology Approaches to Improve and Optimize Drug Therapy for Pregnant and Lactating Women” by Priya Jayachandran, Jane Knöchel, Brian Cicali, and Karen…
Physiologically-based pharmacokinetic modeling can be used to support bioequivalence (BE) assessment of complex and locally acting generic drugs.
A symbiosis between a modeler and a trialist is often required to develop a model-informed drug development strategy. Modelers can design an experiment so the results can be interpreted in…
Background Monkeys and humans share a strong bond, reflected not only in a shared genetic heritage, but in history and folklore. In Chinese literature from the 16th century, Journey to the…
Certara’s Dr. Fran Brown, SVP Drug Development Science, is featured in this recent Pharmaceutical Executive article on the future for using psychedelic drugs to treat mental health conditions. Read this…
Your biotech company has just submitted the marketing application for your first drug product. It’s a moment of celebration after years of hard work! But you know that the reviewers’…
Clients are invited to join Certara at this two-day event to further explore and connect on the future of drug development RADNOR, PA – OCTOBER 24, 2024 – Certara, Inc….
© 2025 Certara. All Rights Reserved. | Privacy policy
